The STOP-CAD study signaled a short course of an antithrombotic regimen might lower ischemic stroke risk in some patients without significantly increasing major bleeding.
New observational data suggested direct oral anticoagulants may be the optimal antithrombotic regime after transcatheter mitral valve replacement; randomized trials were needed.
The phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy vs apixaban in preventing stroke and systemic embolism in patients with AF.